Pertussis vaccine: A critique

Pediatric Infectious Disease Journal

Volumn 28, Issue 3, 2009, Pages 237-241

  Robbins, John B ^c   Schneerson, Rachel ^c   Keith, Jerry M ^c   Miller, Mark A ^a   Kubler Kielb, Joanna ^c   Trollfors, Birger ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

FHA; Genetically inactivated; Monovalent; Pertactin; Pertussis toxin

Indexed keywords

FIMBRIA PROTEIN; IMMUNOGLOBULIN G; PERTUSSIS TOXIN; PERTUSSIS VACCINE; ADHESIN; BORDETELLA VIRULENCE FACTOR; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FILAMENTOUS HEMAGGLUTININ ADHESIN, BORDETELLA PERTUSSIS; INACTIVATED VACCINE; OUTER MEMBRANE PROTEIN; PERTACTIN; PERTUSSIS TOXOID; TOXOID;

ANALYTICAL ERROR; ANTIBODY RESPONSE; DIPHTHERIA; DRUG EFFICACY; HERD IMMUNITY; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION SENSITIVITY; NOTE; PERTUSSIS; PRIORITY JOURNAL; TREATMENT FAILURE; VACCINATION; VACCINE PRODUCTION; ADULT; ANIMAL; ARTICLE; BLOOD; BORDETELLA PERTUSSIS; CHILD; GENETICS; IMMUNOLOGY; MOUSE;

ADHESINS, BACTERIAL; ADULT; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNITY, HERD; IMMUNOGLOBULIN G; MICE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TOXOIDS; VACCINES, INACTIVATED; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 63449098235     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31818a8958     Document Type: Note

References (66)

1. Pittman M. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. Rev Infect Dis. 1979;1:401-412.
2. Robbins JB. Towards a new vaccine for pertussis. In: Microbiology. Washington, DC: ASM; 1984:176-183.
3. Robbins JB, Pittman M, Trollfors B, et al. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr Infect Dis J. 1993;10:795-807.
4. Robbins JB, Schneerson R, Keith JM, et al. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-modified toxoid for DTP. Vaccine. 2007;25:2811-2816.
5. Celentano LP, Massari M, Paramatti D, et al. ; on behalf of the EUVAC-Net Group. Resurgence of pertussis in Europe. Pediatr Infect Dis J. 2005;24: 761-765.
6. Xing DL, Corbel MJ, Dobbelaer R, et al. WHO Working Group on Standardization and Control of Acellular Pertussis Vaccines-Report of a meeting held on March 16-17, 2006, St. Albans, United Kingdom.
7. Schneerson R, Robbins JB, Taranger J, et al. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet. 1996;348:1289 -1292.
8. Ipsen J. Circulating antitoxin at the onset of diphtheria in 425 patients. J Immunol. 1946;54:325-347.
9. Crossley K, Irvine KM, Warren JB, et al. Tetanus and diphtheria immunity in urban Minnesota adults. JAMA. 1979;242:2298-2300.
10. Pappenheimer AMJr. Diphtheria. In: Germanier R, ed. Bacterial Vaccines. New York, NY: Academic Press; 1984:1-36.
11. Heininger U, Cherry JD. Pertussis immunisation in adolescents and adults- Bordetella pertussis epidemiology should guide vaccination and recommendations. Expert Opin Biol Ther. 2006;6:685-687.
12. Linnemann CC Jr, Ramundo N, Perlstein PH, et al. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet. 1975;2:540 -543.
13. Placebo-controlled trial of two acellular pertussis vaccines in Sweden- protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet. 1988;1:955-960.
14. Blackwelder WC, Storsaeter J, Olin P, et al. Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am J Dis Child. 1991;145:1285-1290.
15. Trollfors B, Taranager J, Lagergård T, et al. A placebo-controlled trial of a pertussis toxoid vaccine. N Eng J Med. 1995;333:1045-1050.
16. WHO meeting on case definitions of pertussis. Geneva, Switzerland: World Health Organization MIM/EPI/PERT/91.1; January 10-11, 1991.
17. Hviid A, Stellfeld M, Andersen PH, et al. Impact of routine vaccination with a pertussis vaccine in Denmark. Vaccine. 2004;22:3530-3534.
18. Taranger J, Trollfors B, Bergfors E, et al. Mass vaccination of children with pertussis toxoid- decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis. 2001;33:1004-1010.
19. Broome CV, Fraser DW. Pertussis in the United States, 1979: a look at vaccine efficacy. J Infect Dis. 1981;144:187-190.
20. Meade BD, Kind PD, Ewell JB, et al. In vitro inhibition of murine macrophage migration by Bordetella pertussis lymphocytosis-promoting factor. Infect Immun. 1984;45:718-725.
21. Carbonetti NH, Artamonova GV, Van Rooijen N, et al. Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect Immun. 2007;75:1713-1729.
22. Kendrick P, Eldering G. Significance of bacteriological methods in the diagnosis and control of whooping cough. Amer J Publ Hlth. 1935;25:147-155.
23. Onorato IM, Wassilak SG, Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA. 1992;267:2745-2749.
24. MMWR Recommendations and Reports. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1997;46(RR-7):1-25.
25. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progretto Pertosse Working Group. N Engl J Med. 1996;334:341-348.
26. Gustalsson L, Hallander HO, Reizestgein E, et al. A controlled trial of a two-component acellular, a five-component acellular and a whole cell pertussis vaccine. N Engl J Med. 1996;334:349-355.
27. Jenkinson D. Natural course of 500 consecutive cases of whooping cough: a general population study. BMJ. 1995;310:299-302.
28. Tozzi AE, Rava L, degli Atti MLC, et al. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics. 2003;112:1069-1075.
29. Taranger J, Trollfors B, Lagergård T, et al. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J. 1997;16:180-184.
30. Taranger J, Trollfors B, Bergfors E, et al. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. Pediatrics. 2001;108:E115.
31. Grob PR, Crowder MJ, Robbins JF. Effect of vaccination on severity and dissemination of whooping cough. BMJ. 1981;282:1925-1928.
32. Edwards KE, Decker MD, Mortimer EA. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: W.B. Saunders Co.; 1999:325.
33. Trollfors B, Taranger J, Lagergård T, et al. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. Clin Infect Dis. 1999;28:552-559.
34. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics. 1998;101 (1 Pt 1) 1-11.
35. Sato H, Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun. 1984;46:415-421.
36. Granstrom M, Granstrom G. Serological correlates in whooping cough. Vaccine. 1993;11:445-448.
37. Isacson J, Trollfors B, Taranger J, et al. Acquisition of serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis. Pediatr Infect Dis J. 1995;14: 517-521.
38. Taranger J, Trollfors B, Lagergård T, et al. Parapertussis infection followed by pertussis infection. Lancet. 1994;344:1703.
39. Miller JJ, Saito TM, Silverberg RJ. Parapertussis. Clinical and serologic observations. J Pediatr. 1941;19:229 -240.
40. Bergfors E, Trollfors B, Taranger J, et al. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Int J Infect Dis. 1999;3:140 -146.
41. Edwards KM, Meade BD, Decker MD, et al. Comparison of 12 acellular pertussis vaccines: overview and serologic response. Pediatrics. 1995;96:(3 Pt 2):548-557.
42. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunoge-nicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics. 1997;100:772-788.
43. Charles I, Rodgers B, Musgrave S, et al. Expression of P. 69/pertactin from Bordetella pertussis in a baculovirus/insect cell expression system: protective properties of the recombinant protein. Res Microbiol. 1993;144:681-690.
44. Shahin RD, Brennan MJ, Li ZM, et al. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med. 1990;171:63-73.
45. Hodder SL, Cherry JD, Mortimer EA Jr, et al. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis. 2000;31:7-14.
46. Liese JG, Meschievitz CK, Harzer E, et al. ; Munich Study Group. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J. 1998;16:1038-1044.
47. Kuno-Sakai H, Kimura M, Watanabe H. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan. Biologicals. 2004;32:29 -35.
48. Simondon F, Iteman I, Preziosi MP, et al. Evaluation of an immunoglobulin G enzyme-linked immmunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal. Clin Diag Lab Immunol. 1998;5:130-134.
49. von König CHW, Gounis D, Laukamp S, et al. Evaluation of a single-sample serological technique for diagnosis of pertussis in unvaccinated children. Eur J Clin Microbiol Infect Dis. 1999;18:341-345.
50. Baughgman AL, Bisgard KM, Edwards KM, et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diag Lab Immunol. 2004;11:1045-1053.
51. Gransrom M, Olinder-Nielsen AM, Homblad O, et al. Specific immunoglobulin for treatment of whooping cough. Lancet. 1991;338:1230-1233.
52. Taranger J, Trollfors B, Lagergård T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis. 2000;181:1010-1013.
53. Watanabe M, Connelly B, Weiss AA. Characterization of serological responses to pertussis. Clin Vacc Immunol. 2006;13:341-348.
54. Olin P, Rasmussen F, Gustafsson L, et al. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet. 1997;350:1569-1577.
55. Zackrisson G, Taranger J, Trollfors B. History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J Pediatr. 1990;116:190-194.
56. Carlsson R-M, Claesson BO, Selstam U, et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J. 1998;17:1026-1033.
57. Storsaeter J, Hallander HO, Gustafsson L, et al. Low levels of anti-pertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine. 2003;21:3542-3549.
58. Burnette WN, Cielpak W, Mar VL, et al. Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science. 1988;242:72-254.
59. Pizza M, Covacci A, Bartoloni B, et al. Mutants of pertussis toxin suitable for vaccine development. Science. 1989;246:497-500.
60. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 2004. MMWR. 2006;53:1-79.
61. Keitel WA, Muenz LR, Decker MD, et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis. 1999;180:397- 403.
62. Tozzi AE, Anemona A, Stefanelli P, et al. Progetto Pertosse Study Group. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics. 2001;107:E25.
63. Feikin DR, Lezotte DC, Hamman RF, et al. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA. 2000;284:3145-3150.
64. Schloesser RL, Fischer D, Otto W, et al. Safety and immunogenicity of acellular pertussis vaccine in premature infants. Pediatrics. 1999;103:e60.
65. Robinson MJ, Heal C, Gardner E, et al. Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who received dexameth-asone for chronic lung disease. Pediatrics. 2004;113:733-737.
66. Slack MH, Schapira D, Thwaites RJ, et al. Acellular pertussis vaccine given by accelerated schedule: response of preterm infants. Arch Dis Child Fetal Neonatal Ed. 2004;89:F57-F60.